This company listing is no longer active
Acerus Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
-22.8%
Tasa de crecimiento de los beneficios
23.7%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 23.1% |
| Tasa de crecimiento de los ingresos | -32.5% |
| Rentabilidad financiera | n/a |
| Margen neto | -924.3% |
| Última actualización de beneficios | 30 Sep 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
Auditors Have Doubts About Acerus Pharmaceuticals (TSE:ASP)
Mar 14
Have Insiders Been Buying Acerus Pharmaceuticals Corporation (TSE:ASP) Shares?
Mar 12Acerus Pharmaceuticals' (TSE:ASP) Shareholders Are Down 88% On Their Shares
Jan 22The Independent Director of Acerus Pharmaceuticals Corporation (TSE:ASP), Stephen Gregory, Just Bought 52% More Shares
Nov 30
Desglose de ingresos y gastos
Cómo gana y gasta dinero Acerus Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Sep 22 | 3 | -28 | 20 | 7 |
| 30 Jun 22 | 3 | -29 | 20 | 7 |
| 31 Mar 22 | 3 | -28 | 22 | 5 |
| 31 Dec 21 | 2 | -34 | 22 | 5 |
| 30 Sep 21 | 2 | -32 | 20 | 4 |
| 30 Jun 21 | 2 | -34 | 21 | 3 |
| 31 Mar 21 | 1 | -33 | 20 | 3 |
| 31 Dec 20 | 1 | -24 | 18 | 3 |
| 30 Sep 20 | 1 | -21 | 17 | 2 |
| 30 Jun 20 | 1 | -19 | 14 | 2 |
| 31 Mar 20 | 2 | -16 | 12 | 2 |
| 31 Dec 19 | 4 | -16 | 10 | 3 |
| 30 Sep 19 | 5 | -17 | 9 | 3 |
| 30 Jun 19 | 7 | -16 | 8 | 3 |
| 31 Mar 19 | 8 | -19 | 9 | 3 |
| 31 Dec 18 | 7 | -19 | 9 | 2 |
| 30 Sep 18 | 8 | -16 | 8 | 3 |
| 30 Jun 18 | 7 | -16 | 8 | 2 |
| 31 Mar 18 | 7 | -11 | 7 | 2 |
| 31 Dec 17 | 7 | -9 | 7 | 2 |
| 30 Sep 17 | 6 | -7 | 6 | 2 |
| 30 Jun 17 | 6 | -5 | 6 | 2 |
| 31 Mar 17 | 15 | 3 | 6 | 2 |
| 31 Dec 16 | 24 | 11 | 5 | 2 |
| 30 Sep 16 | 31 | 3 | 5 | 2 |
| 30 Jun 16 | 32 | 5 | 5 | 2 |
| 31 Mar 16 | 24 | -3 | 5 | 3 |
Ingresos de calidad: ASP is currently unprofitable.
Margen de beneficios creciente: ASP is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: ASP is unprofitable, and losses have increased over the past 5 years at a rate of 22.8% per year.
Acelerando crecimiento: Unable to compare ASP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: ASP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.3%).
Rentabilidad financiera
Alta ROE: ASP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.